Chemical Abstracts, vol. 111, No. 26, Dec. 25, 1989, Columbus, Ohio, US; abstract No. 239514, XP-002102408, see abstract & JP 01 016799 A (Toyo Jozo), Jan. 20, 1989. |
Reeve et al., “Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial”, Br. Med. J., 280(6228):1340-1344, 1980. |
Reeve et al., “Anabolic Effect of Low Doses of a Fragment of Human Parathyroid Hormone on the Skeleton in Postmenopausal Osteoporosis”, The Lancet, 1:1035-1038, 1976. |
Reeve et al., “Preliminary Trial of Low Doses of Human Parathyroid Hormone 1-34 Peptide in Treatment of Osteoporosis”, Calcif. Tissue Res., 21:469-477, 1976. |
Hodsman et al., “Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients”, Bone and Mineral, 9(2):137-152, 1990. |
Tsai et al., “Bone Responsiveness to Parathyroid Hormone in Normal and Osteoporotic Postmenopausal Women”, J. Clin. Endocrinol Metab., 69(5):1024-1027, 1989. |
Isaac et al., “Absence of Effect of 1-34 h PTH on Plasma TSH, GH, FSH, LH, ACTH and Cortisol in Normal Man”, Horm. Metab. Res., 12(9):487-488, 1980. |
Law et al., “Rapid Development of Renal Resistance to Low Doses of Synthetic Bovine Parathyroid Hormone Fragment 1-34”, J. Clin Invest., 72(3):1106-1113, 1983. |
Hulter et al., “Chronic Continuous PTH Infusion Results in Hypertension in Normal Subjects”, J. Clin Hypertens, 2(4):360-370, 1986. |
Hodsman et al., “Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients”, 14(1):67-83, 1991. |
Packaging Drugs and Pharmaceuticals, W.A. Jenkins and K.R. Osborn, Technomic Pub. 1993. |